Calidad de vida en pacientes con metástasis óseas por carcinoma pulmonar tratados con ácido zoledrónico

Iván Ramón Concepción, Jorge Luis Soriano García, Dunia Morales Morgado, Mayté Lima Pérez, Noyde Batista Albuerne, Vilma Fleites Calvo, Masiel González Meisozo

Texto completo:

PDF

Resumen

Introducción: Las metástasis óseas por cáncer de pulmón tienen un impacto negativo en la calidad de vida.

Objetivo: Evaluar calidad de vida relacionada con salud en pacientes con metástasis óseas tratados con ácido zoledrónico.

Métodos: Se realizó un estudio observacional prospectivo y descriptivo a 38 pacientes del Servicio de Oncología Clínica del Hospital “Hermanos Ameijeiras”. Se evaluó el dolor con la Escala Visual Análoga y la calidad de vida relacionada con salud mediante módulo EORTC QLQ-BM22. Criterios de inclusión: >18 años y < 80 años de edad, ECOG < 3, expectativa de vida > 6 meses, función normal de los órganos y de la médula ósea, doce meses de seguimiento y se administró 4 mg endovenoso de zoledrónico cada 21-28 días.

Resultados: Se obtuvo una eficacia analgésica a los doce meses, con escala visual analgésica y mejoría de la calidad de vida relacionada con salud, en escala de síntomas. El grupo que alcanzó al menos 6 meses con zoledrónico, tuvo mayor frecuencia de respuesta parcial. No pudo evaluarse calidad de vida relacionada con salud a doce meses por interrupción temprana del fármaco por mal pronóstico: metástasis viscerales al diagnóstico de metástasis óseas, ˃ 65 años, progresión del cáncer, y deterioro de estado funcional.

Conclusiones: El diagnóstico oportuno de las metástasis óseas, y los tratamientos específicos del cáncer prostático en combinación con zoledrónico, mejoran la calidad de vida relacionada con salud en pacientes con metástasis óseas.

Referencias

Huang J-F, Shen J, Li X, Rengan R, Silvestris N, Wang M, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020; 8(7): 482.

http://dx.doi.org/10.21037/atm.2020.03.55.

Balaji Z, Dhiyaneswaran S, Jerin Joy. Skeletal metastasis-an epidemiological study. Indian J Surg Oncol. 2018; 9(1): 46–51.

http://dx.doi.org/10.1007/s13193-017- 706-6.

Drudge-Coates L, van Muilekom E, de la Torre-Montero JC, Leonard K, van Oostwaard M, Niepel D, et al. Management of bone health in patients with cancer: a survey of specialist nurses. Supportive Care in Cancer. 2020; 28: 1151–1162. https://doi.org/10.1007/s00520-019-04858-2.

Lang J, Zhao Q, He Y, Yu X. Bone turnover markers and novel biomarkers in lung cancer bone metastases, Biomarkers. 2018; 23: 518-526.

https://doi.org/10.1080/1354750X.2018.1463566.

Schmid-Alliana A, Schmid-Antomarchi H, Al-Sahlanee R, Lagadec P, Scimeca JC, Verron E. Understanding the progression of bone metastases to identify novel therapeutic targets. Rev Int J Mol Sci. 2018; 19: 148.

https://doi.org/10.3390/ijms19010148.

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis Nat Rev Cancer. 2019; 19(1): 9–31.

https://doi.org/10.1038/s41568-018-0081-9.

Maeda K, Kobayashi Y, Koide M, Uehara Sh, Okamoto M, Ishihara A, et al. The regulation of bone metabolism and disorders by Wnt signaling. Review. Int J Mol Sci. 2019; 20: 5525. https://doi.org/10.3390/ijms20225525.

Zhao Q, Chang L, Yin X, Tang M, Guojing L, Xiang Ch, et al. Lung cancer cells derived circulating mir-21 promotes differentiation of monocytes into osteoclasts. Onco Targets Ther. 2020; 13: 2643-2656.

https://doi.org/10.2147/OTT.S232876.

Zhang, G et al. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep. 2017; 7: 42979. https://doi.org/10.1038/srep42979.

Wang Sh, Niu X, Bao X, Wang Q, Shang J, Lu Sh, Wang Y, et al. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. Oncol Rep. 2019; 41: 2636-2646.

https://doi.org/10.3892/or.2019.7080.

Wang Z, Qiao D, Lu Y, Curtis D. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist. 2015; 20(4): 440-449. https://doi.org/10.1634/theoncologist.2014-0328.

Von Moos R, Body JJ, Egerdie B, et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer. 2016; 24(3): 1327-1337.

https://doi.org/10.1007/s00520-015-2908-1.

Hussain A, Leeb RJ, Graff JN, Halabi S. The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Crit Rev Oncol Hematol. 2019; 139: 108–116.

https://doi.org/10.1016/j.critrevonc.2019.04.020.

Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012; 20: 2985–2998. https://doi.org/10.1007/s00520-012-1563-z.

Langer H. Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates. Rev Lung Cancer. 2010; 67: 4–11.

Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exper Clin Cancer Res. 2017; 36:108. https://doi.org/10.1186/s13046-017-0578-1.

Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Health Qual Life Outcomes. 2020; 18: 136. https://doi.org/10.1186/s12955-020-01344-w.

Chow N, et al, on behalf of the European Organization for Research Treatment of Cancer Quality of Life Group. International field testing of the reliability and validity of the EORTC QLQ-BM22 Module to assess health-related quality of life in patients with bone metastases. Cancer. 2012; 118: 1457 - 1465. https://doi.org/10.1002/cncr.26410.

Mendez LC, Raman S, Wan BA, da Silva JL, Moraes FY, Lima KM, et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort. Ann Palliat Med. 2017; 6(Suppl 1): S65-S70.

https://doi.org/10.21037/apm.2017.04.06.

Raman S, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, et al. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Qual Life Res. 2016; 25(10): 2535–2541.

https://doi.org/10.1007/s11136-016-1308-4.

Hendriks LE, Hermans BC, van den Beuken—van Everdingen MH, Hochstenbag MM, Dingemans AM. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non– small cell lung cancer and bone metastases: a systematic review. J Thoracic Oncol. 2015; 11(2): 155-173. https://doi.org/10.1016/j.jtho.2015.10.001.

Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Curr Opin Oncol. 2015; 27(2): 94–101.

https://doi.org/10.1097/cco.0000000000000164.

Mok TS, Wu YL, Ahn MJ et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376: 629-640. https://doi.org/10.1056/NEJMoa1612674.

Koufopoulou C, Mosa E, Charalampaki N, Nikolaou M, Tsoukalas N, Nixon I, et al. Evaluation of quality of life outcomes following palliative radiotherapy in bone metastases: A literature review. J Buon. 2019; 24(5): 1747-1760. PMID: 31786834.

Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Copyright (c) 2020 Jorge Luis Soriano García

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.